The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase--GW311616A a development candidate
Macdonald, S.J., Dowle, M.D., Harrison, L.A., Shah, P., Johnson, M.R., Inglis, G.G., Clarke, G.D., Smith, R.A., Humphreys, D., Molloy, C.R., Amour, A., Dixon, M., Murkitt, G., Godward, R.E., Padfield, T., Skarzynski, T., Singh, O.M., Kumar, K.A., Fleetwood, G., Hodgson, S.T., Hardy, G.W., Finch, H.(2001) Bioorg Med Chem Lett 11: 895-898
- PubMed: 11294386 
- DOI: https://doi.org/10.1016/s0960-894x(01)00078-6
- Primary Citation of Related Structures:  
1HV7 - PubMed Abstract: 
The discovery of a potent intracellular inhibitor of human neutrophil elastase which is orally active and has a long duration of action is described. The pharmacodynamic and pharmacokinetic properties of a trans-lactam development candidate, GW311616A, are described.
Organizational Affiliation: 
Medicinal Chemistry 2, GlaxoWellcome Medicines Research Centre, Stevenage, UK. [email protected]